Trial · NCT01936974
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
NCT01936974, Phase 2, Terminated, Western Regional Medical Center; results first posted 2017-10-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma. Trials, record NCT01936974. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01936974
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- NCT number
- NCT01936974
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Western Regional Medical Center
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Interventions
- Gemcitabine, Bevacizumab, Carboplatin, Cisplatin, Oxaliplatin
- First posted
- 2013-09-06
- Last updated
- 2018-02-20
- Results first posted
- 2017-10-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival | One Year | Evaluate progression-free survival between the two regimens. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival | One Year | Data not collected. The study has been terminated due to the PI no longer being employed at CTCA and not having rights to the trial information.After much effort, results were not able to be retained. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Platinum, Gemcitabine and Bevacizumab | 2 | |
| Overall Study | STARTED | Gemcitabine and Bevacizumab | 5 | |
| Overall Study | COMPLETED | Platinum, Gemcitabine and Bevacizumab | 0 | |
| Overall Study | COMPLETED | Gemcitabine and Bevacizumab | 0 | |
| Overall Study | NOT COMPLETED | Platinum, Gemcitabine and Bevacizumab | 2 | |
| Overall Study | NOT COMPLETED | Gemcitabine and Bevacizumab | 5 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Platinum, Gemcitabine and Bevacizumab | 0 | 0 |
| Total, all-cause mortality | Gemcitabine and Bevacizumab | 0 | 0 |
| Total, other adverse events | Platinum, Gemcitabine and Bevacizumab | 0 | 0 |
| Total, other adverse events | Gemcitabine and Bevacizumab | 0 | 0 |
| Total, serious adverse events | Platinum, Gemcitabine and Bevacizumab | 0 | 0 |
| Total, serious adverse events | Gemcitabine and Bevacizumab | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01936974
GET https://conductscience.org/api/trials/v1/NCT01936974/registered